Navigation Links
Novel drug holds promise for treatment of Rheumatoid Arthritis

The successful completion of Phase II clinical trials of a novel drug called dnaJP1 for treatment of osteoarthritis that works without suppressing the immune system has been announced by Researchers at the University of California//.

Rheumatoid arthritis is a chronic, painful disease affecting millions worldwide. It is thrice more common in women in men and affects people of any age. It strikes joints on both sides of the body, such as the hands or feet or knees but can also affect the skin, eyes, lungs, heart, blood, nerves or kidneys. It is an incurable disease, with most therapies focusing on symptom relief.

Current medications for treating RA range from anti-inflammatory drugs, such as aspirin, to corticosteroids and medicines that alleviate symptoms by suppressing or killing the body’s immune response, basically crippling the body’s ability to defend itself against other infectious diseases or cancer.

The novel drug is a peptide derived from a naturally occurring protein, dnaJ, which generates inflammation in RA patients. The drug when administered disturbs the immune system, which is then activated to kill and clear foreign pathogens in the body. This results in an enhanced immune response which is not possible otherwise. The drug would have to administered through the oral route as the immune set up in the gut has the potential to educate the body to view a protein as one that isn’t dangerous or foreign. DnaJP1 was found effective in a double-blind, placebo-controlled trial sponsored by the National Institutes of Health, which took place between 2000 and 2005 and involved about 160 patients.

Patients received 25mg of dnaJP1 daily by mouth for six months, and the treatment was found to be safe and well-tolerated. When compared with a placebo, patients in the treatment group experienced lessening of symptoms such as swollen joints, tenderness, pain and decreased mobility. Improvement was particularly significant at the fol low up visits, indicating a lasting effect of the drug.

The first two trials of dnaJP1 have not raised any significant safety concerns and offer an improved treatment option for patients with rheumatoid arthritis, especially while taking into consideration the side effects associated with current available therapy. The researchers intend to get approval and funding to move into Phase III clinical trials.

This is a very exciting and novel therapeutic approach, which holds the promise to be an entirely new type of immunomodulatory drug – one that can shape a patient’s immune system, rather than suppressing it. With such an advance, the treatment of rheumatoid arthritis seems a potential reachable realit.

Related medicine news :

2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:

(Date:11/30/2015)... NC (PRWEB) , ... November 30, 2015 , ... ... practices in 2016. In 2016, expected coding changes are likely to include new ... service codes. It’s not easy to understand the effects of code changes in ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Bayco Products, Inc today announced the introduction ... each. Available in a choice of three different colors; red ( NSP-1632 ), yellow ( ... run up to 18 hours in constant-on mode, or 27 hours in blinking strobe mode ...
(Date:11/29/2015)... ... November 30, 2015 , ... Gift ideas for the natural ... All products are available on Amazon or its webstore. , "We love the ... USDA Certified Organic Sesame Oil for Oil Pulling," says Kathy Heshelow, founder of ...
(Date:11/29/2015)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... November 29, 2015 , ... ... football games, basketball games. Things that as a Mother and Wife would love to ... was no mistake that I just happened to call Dr. Zaidan first. They have ...
(Date:11/29/2015)... ... ... NewsWatch featured X-wing as part of its monthly Tech Report, which features the ... special reporter for NewsWatch, conducted the review and shared with viewers how Woody Guthrie’s ... flying cars are about to become a reality. Where’s the idea from? With inspiration ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 2015   Nuance Communications, Inc. (NASDAQ: ... Company (NDSC) today jointly announced a new integrated ... utilize the American College of Radiology,s (ACR) Imaging 3.0™ ... comply with current and emerging value-based payment models ... By combining clinical decision support, radiology reporting and ...
(Date:11/30/2015)... N.J. , Nov. 30, 2015  Novartis will ... at the 57 th American Society of Hematology ... lymphomas and myelomas as well as supportive care, including ... addition to personalized cell therapies. The ASH Annual Meeting ... Florida . Novartis Oncology . "We ...
(Date:11/30/2015)... REHOVOT, Israel , Nov. 30, 2015 ... focused on acquiring and developing innovative therapies for ear, ... of Keith A. Katkin as chairman of ... Flesher , chief executive officer for OticPharma, Ltd.  "Keith ... As chairman, he will be able to share this ...
Breaking Medicine Technology: